Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
5(62.5%)
Phase 2
3(37.5%)
8Total
Phase 1(5)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01904162Phase 1Completed

Effect of Age and Gender on the PK and Tolerability of Finafloxacin

Role: lead

NCT01928433Phase 2Completed

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

Role: lead

NCT01907867Phase 1Completed

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Role: lead

NCT01910883Phase 1Completed

Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Role: lead

NCT00723502Phase 2Completed

Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients

Role: lead

NCT00722735Phase 2Completed

Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)

Role: lead

NCT00483158Phase 1Completed

First Time in Man Study of Finafloxacin Hydrochloride

Role: lead

NCT00492271Phase 1Terminated

First Time in Man Trial for Friulimicin B

Role: lead

All 8 trials loaded